Biosimilars in oncology: key role of nurses in patient education

Author:

Waller Cornelius F1ORCID,Friganović Adriano23ORCID

Affiliation:

1. Department of Haematology, Oncology & Stem Cell Transplantation, University Medical Centre Freiburg & Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

2. Department of Anesthesiology & Intensive Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia

3. Department of Nursing, University of Applied Health Sciences, 10000 Zagreb, Croatia

Abstract

Biosimilars have the potential to lower costs and increase patient access to life-saving cancer therapies. However, lack of familiarity with biosimilars can be a barrier to their adoption, limiting their health and economic benefits. As highly trusted healthcare providers, nurses play integral roles in patient education. This review aims to help prepare nurses to respond to potential questions from patients on biosimilars. The regulation, use and potential benefits of biosimilars are discussed, with a focus on biosimilars in oncology. Overall, biosimilars are highly regulated medicines that provide comparable benefits to available biologics. Nurses can influence the adoption of biosimilars through patient education and can impact the future of the field in their expanding roles within health care systems.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Reference28 articles.

1. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements

2. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars

3. Patent expiry dates for biologicals: 2017 update

4. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. (2014). www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf

5. US FDA. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. (2015). www.fda.gov/media/82647/download

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3